Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update
Ra Capital Management, L.P. Sells 484,104 Shares of Vor Biopharma (NASDAQ:VOR) Stock
Ra Capital Management, L.P. Sells 135,201 Shares of Vor Biopharma (NASDAQ:VOR) Stock
Vor Biopharma: It's A Game Of Wait And See
Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease
What's Behind The Jump In Vor Biopharma Stock?
Vor Bio Announces $75 Million Private Placement with TCGX
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of “Moderate Buy” from Brokerages
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
Vor Bio Announces $150 Million Private Placement
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Hold” from Brokerages
Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN)
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Vor Bio to Participate in Upcoming Investor Conferences
ACTO STELLT ACTOVERSE VOR: EIN MARKTPLATZ FÜR PARTNERLÖSUNGEN ZUR FÖRDERUNG VON INNOVATION UND EFFIZIENZ IM BEREICH EXZELLENZ AUF DEM VEEVA COMMERCIAL SUMMIT EUROPE
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
Vor Bio Appoints Navid Z. Khan, Ph.D.